Tumor immunotherapy target and application thereof
AssigneeBeijing Proteome Research Center
InventorsLi Tang, Fuchu He, Di Liu, Qian Lu
Life of this patent
Estimating the term…
Abstract
The present invention provides a tumor immunotherapy target and use thereof, specifically provides use of the LSECtin expressed by infiltrating tumor-associated macrophage and BTN3A3 expressed by tumor solely or in combination as a target in tumor immunotherapy, and further provides a substance capable of inhibiting the activity of LSECtin expressed by infiltrating tumor-associated macrophage, the activity of BTN3A3 expressed by tumor, or the interaction of the LSECtin with BTN3A3, including RNA molecules, fusion protein BTN3A3-Ig, and monoclonal antibody 5E08, which can be used as an active ingredient to prepare a tumor immunotherapy drug, and is suitable for industrial applications.
Claims2
A method for cancer immunotherapy, wherein the method comprises administering an effective amount of a recombinant protein named BTN3A3-Ig to a cancer patient to block the interaction between LSECtin and BTN3A3, wherein the amino acid sequence of the BTN3A3-Ig is set forth in SEQ ID NO:
- 9;
- and wherein the cancer is a cancer in which tumor-associated macrophages express LSECtin and tumor cells express BTN3A3.
Dependencies are inferred from the claim text.